Immix Biopharma, Inc. Common Stock
Here’s whether Immix Biopharma, Inc. Common Stock (IMMX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+0.70% over 10 days); RSI 43 — healthy momentum range; strong 1-year return of +264.3%; rising volume confirms the move (1.50x 30d avg). Concerns: below the 50-day MA (medium-term momentum negative). Currently 24.4% off its 52-week high. Score: +5/7.
IMMX is holding above its long-term 200-day MA ($5.73) but has slipped below the 50-day MA ($9.46), pointing to short-term weakness in an otherwise intact trend. An RSI of 43.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +264.3% compares to +27.9% for SPY (beat the market by 236.4%). The current 24.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.